Effect of a Targeted Notification and Clinical Support Pathway on Individuals With Left Ventricular Hypertrophy (NOTIFY-LVH)
Hypertrophy, Left Ventricular, Hypertension, Cardiomyopathies
About this trial
This is an interventional treatment trial for Hypertrophy, Left Ventricular focused on measuring Left ventricular hypertrophy, Pragmatic clinical trial
Eligibility Criteria
Inclusion Criteria: Age 30-75 years Transthoracic echocardiogram as of 1/1/2019 LVH on echocardiogram Mass General Brigham PCP affiliation with at least 1 PCP practice visit within the last 24 months Exclusion Criteria: Current or previous outpatient blood pressure medication prescription Moderate or severe aortic stenosis Severe concentric LVH Asymmetric LVH History of prosthetic heart valve Bicuspid aortic valve Known cardiomyopathy (or had an outpatient visit diagnosis for a cardiomyopathy) Autonomic dysfunction History of heart or lung transplantation Active cancer treatment plan Active pregnancy Dementia Individuals whose primary address is in a nursing home or long-term care facility
Sites / Locations
- Massachusetts General Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Intervention: Population Health Coordinator
Observation: Usual Care
For subject randomized to the intervention arm, population health coordinators will notify the established longitudinal specialty clinician (cardiologist or nephrologist) or the primary care provider (PCP) that their patient has a recent echocardiogram demonstrating left ventricular hypertrophy (LVH). The outpatient clinician will be notified via the electronic health record (EHR) messaging system that the finding of LVH -- in the absence of significant valvular heart disease or a previously diagnosed cardiomyopathy -- may reflect undiagnosed or untreated hypertension.
Those subjects randomized to the observation arm will receive usual care and their clinicians will not be notified about the finding of LVH on a prior echocardiogram until after study completion.